Portolan Capital Management LLC Purchases 141,749 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

Portolan Capital Management LLC increased its position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 21.1% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 812,630 shares of the medical equipment provider’s stock after purchasing an additional 141,749 shares during the quarter. Lantheus accounts for 4.9% of Portolan Capital Management LLC’s investment portfolio, making the stock its biggest holding. Portolan Capital Management LLC owned approximately 1.17% of Lantheus worth $72,698,000 at the end of the most recent quarter.

A number of other hedge funds have also made changes to their positions in the company. State of New Jersey Common Pension Fund D raised its holdings in shares of Lantheus by 0.4% in the fourth quarter. State of New Jersey Common Pension Fund D now owns 26,428 shares of the medical equipment provider’s stock worth $2,364,000 after acquiring an additional 115 shares during the last quarter. Bleakley Financial Group LLC raised its stake in Lantheus by 6.1% in the 4th quarter. Bleakley Financial Group LLC now owns 2,237 shares of the medical equipment provider’s stock valued at $200,000 after purchasing an additional 129 shares during the last quarter. Avantax Advisory Services Inc. lifted its holdings in Lantheus by 5.9% in the 4th quarter. Avantax Advisory Services Inc. now owns 2,382 shares of the medical equipment provider’s stock valued at $213,000 after purchasing an additional 132 shares in the last quarter. Foundry Partners LLC boosted its stake in shares of Lantheus by 4.5% during the 4th quarter. Foundry Partners LLC now owns 3,103 shares of the medical equipment provider’s stock worth $278,000 after purchasing an additional 133 shares during the last quarter. Finally, UMB Bank n.a. grew its holdings in shares of Lantheus by 31.5% during the fourth quarter. UMB Bank n.a. now owns 559 shares of the medical equipment provider’s stock worth $50,000 after buying an additional 134 shares in the last quarter. Hedge funds and other institutional investors own 99.06% of the company’s stock.

Analysts Set New Price Targets

LNTH has been the topic of a number of analyst reports. Truist Financial raised their target price on shares of Lantheus from $120.00 to $127.00 and gave the stock a “buy” rating in a research report on Thursday, February 27th. JMP Securities reissued a “market outperform” rating and issued a $112.00 price target on shares of Lantheus in a research note on Tuesday, January 14th. B. Riley dropped their price objective on shares of Lantheus from $127.00 to $122.00 and set a “buy” rating for the company in a research note on Friday, March 21st. Finally, The Goldman Sachs Group began coverage on shares of Lantheus in a research report on Wednesday, December 18th. They issued a “buy” rating and a $143.00 target price on the stock. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $129.43.

Lantheus Trading Up 3.5 %

Shares of LNTH stock opened at $102.00 on Monday. The company’s fifty day simple moving average is $94.00 and its 200-day simple moving average is $95.56. Lantheus Holdings, Inc. has a 52 week low of $59.56 and a 52 week high of $126.89. The company has a market cap of $6.98 billion, a PE ratio of 16.97 and a beta of 0.20.

Lantheus (NASDAQ:LNTH) last posted its earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 EPS for the quarter, missing analysts’ consensus estimates of $1.57 by ($0.23). Lantheus had a return on equity of 44.29% and a net margin of 28.57%. The firm had revenue of $391.11 million for the quarter, compared to analyst estimates of $376.61 million. Equities research analysts expect that Lantheus Holdings, Inc. will post 6.01 EPS for the current fiscal year.

Insider Buying and Selling at Lantheus

In other news, Director Mary Anne Heino sold 53,107 shares of the stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $94.35, for a total transaction of $5,010,645.45. Following the transaction, the director now owns 440,399 shares of the company’s stock, valued at approximately $41,551,645.65. This trade represents a 10.76 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director James H. Thrall sold 1,000 shares of Lantheus stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $94.76, for a total value of $94,760.00. Following the completion of the transaction, the director now owns 33,207 shares of the company’s stock, valued at approximately $3,146,695.32. The trade was a 2.92 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 64,109 shares of company stock worth $6,110,806 in the last 90 days. 1.50% of the stock is owned by corporate insiders.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.